ANTIVIRAL PHARMACEUTICAL COMPOSITION
Pharmaceutical compositions are described comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of an infection with rhinovirus or respiratory syncytial virus in a human. Particularly, the viral infection is HRV-C15, HRV-A16, or HRV-B14 infection or RSV type A infection. There are also described pharmaceutical compositions comprising fucoidan for use in a method for prevention of rhinovirus spread or respiratory syncytial virus spread in a human population, wherein subjects of the population are tested for infection with HRV-C15, HRV-A16, or HRV-B14 or RSV type A and infected subjects are treated with intranasal administration of the pharmaceutical composition.
1 . Pharmaceutical composition comprising fucoidan for use in a method for the treatment or the prevention, by intranasal administration, of an infection with rhinovirus in a human.
2 . Pharmaceutical composition for use according to claim 1 , wherein the infection is HRV-C15 infection.
3 . Pharmaceutical composition for use according to claim 1 , wherein the infection is HRV-A16 infection.
4 . Pharmaceutical composition for use according to claim 1 , wherein the infection is HRV-B14 infection.
5 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is a nasal spray.
6 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered to nasal epithelium of a subject.
7 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition comprises 0.1% to 2.7% (w/w) fucoidan.
8 . Pharmaceutical composition for use according to claim 1 , comprising fucoidan in a concentration of about 1.250 μg/ml to about 20.000 μg/ml.
9 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is an aqueous solution.
10 . Pharmaceutical composition for use according to claim 9 , wherein the pharmaceutical composition comprises a sodium chloride solution.
11 . Pharmaceutical composition for use according to claim 10 , wherein the sodium chloride solution is isotonic.
12 . Pharmaceutical composition for use according to claim 1 , wherein the pharmaceutical composition is administered intranasally two or three times daily into each nostril of a subject.
13 . Pharmaceutical composition for use according to claim 1 , wherein the
pharmaceutical composition is administered in a dose of 1 mg to 4 mg fucoidan into each nostril of a subject per administration.
14 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan is an extract of Undaria pinnatifida.
15 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has an average molecular weight from 50 kDa to 120 kDa, determined by size exclusion chromatography, with a mobile phase comprising 150 mM NaCl and having pH 6.
16 . Pharmaceutical composition for use according to claim 15 , wherein the fucoidan has an average molecular weight from 70 kDa to 105 kDa, determined by size exclusion chromatography, with a mobile phase comprising 150 mM NaCl and having pH 6.
17 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has an average molecular weight of 150 kDa and a lower molecular weight cut-off of 10 kDa.
18 . Pharmaceutical composition for use according to claim 1 , wherein the fucoidan has a sulfate content of 20% to 40% (w/w).
19 . Pharmaceutical composition for use according to claim 1 , wherein the method of treatment comprises reducing rhinovirus load in a subject.
20 . Pharmaceutical composition for use according to claim 19 , wherein the rhinovirus load is determined by RT-PCR, performed on a nasal swab specimen from the subject.
21 . Pharmaceutical composition for use according to claim 1 , wherein the method of treatment comprises reducing rhinovirus genome copy number in a subject.
22 . Pharmaceutical composition comprising fucoidan for use in a method for prevention of spread of rhinovirus or respiratory syncytial virus in a human population, wherein subjects are tested for infection with rhinovirus or respiratory syncytial virus and infected subjects are treated with intranasal administration of the pharmaceutical composition.
23 . Method of treating or preventing rhinovirus infection, the method comprising intranasally administering to a mammalian subject in need thereof a pharmaceutically effective amount of a pharmaceutical composition comprising fucoidan.
24 . Use of fucoidan for the manufacture of a medicament for the treatment or prevention of rhinovirus infection in a subject.